Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alkermes PLC

28.77
+0.0000
Pre-market: 28.800.0300+0.10%08:00 EDT
Volume:2.42M
Turnover:69.44M
Market Cap:4.74B
PE:13.26
High:28.97
Open:28.97
Low:28.31
Close:28.77
Loading ...

Earnings Flash (ALKS) Alkermes Posts Q1 EPS of $0.13, vs. FactSet Est of $0.05

MT Newswires Live
·
1 hour ago

BRIEF-Alkermes Q1 Revenue USD 306.5 Million Vs. IBES Estimate USD 304.1 Million

Reuters
·
1 hour ago

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
2 hours ago

Do Options Traders Know Something About Alkermes Stock We Don't?

Zacks
·
Yesterday

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

PR Newswire
·
Yesterday

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
29 Apr

Alkermes Is Maintained at Neutral by UBS

Dow Jones
·
29 Apr

Alkermes price target lowered to $33 from $38 at UBS

TIPRANKS
·
28 Apr

Alkermes to Report First Quarter Financial Results on May 1, 2025

THOMSON REUTERS
·
18 Apr

BRIEF-Alkermes - CFO Iain M. Brown Passes Away - SEC Filing

Reuters
·
16 Apr

Alkermes Plc - CFO Iain M. Brown Passes Away - SEC Filing

THOMSON REUTERS
·
16 Apr

Alkermes Down over 8%, On Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones
·
10 Apr

RBC Trims Price Target on Alkermes to $39 From $40, Keeps Sector Perform Rating

MT Newswires Live
·
03 Apr

Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

Zacks
·
02 Apr

Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia

Reuters
·
01 Apr

BRIEF-Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

Reuters
·
01 Apr

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating Alks 2680 for the Treatment of Idiopathic Hypersomnia

THOMSON REUTERS
·
01 Apr

Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating

MT Newswires Live
·
27 Mar

Alkermes Is Maintained at Buy by Deutsche Bank

Dow Jones
·
27 Mar

Alkermes Plc : Deutsche Bank Raises Target Price to $52 From $40

THOMSON REUTERS
·
27 Mar